Transaction DateRecipientSharesTypePriceValue
Moderna logo

Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 5/10.

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA) Its product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rose and Kenneth R. Chien in 2010.

Ticker: MRNA
Sector: Health Technology
Industry: Biotechnology
SEC Central Index Key (CIK): 737207
Employees: 830
Exchange: NASDAQ
Auditor Opinion:

Disclosure Language changes
Red Flags
Assets, Current: $152 Th (-63%)
Assets: $152 Th (-63%)
Accounts Payable, Current: $2 M (56%)
Accrued Liabilities, Current: $2 M (56%)
Liabilities, Current: $13 M (28%)
Liabilities: $13 M (28%)
Common Stock, Value, Issued: $65 Th (0%)
Common Stock, Shares, Issued: $11 M (0%)
Retained Earnings (Accumulated Deficit): $43 M (0%)
Stockholders' Equity (Parent): $13 M (0%)
Liabilities and Equity: $152 Th (-63%)
Sales and Marketing: $13 Th (-98%)
General and Administrative Expenses: $343 Th (-61%)
Operating Income/Loss: $356 Th (-78%)
Income before taxes: $900 Th (-66%)